A clinical study involving 564 adults (BMI 30-40 kg/m2, without T2DM) found that compared with orlistat (3120 mg, weight loss of 4.1 kg), LIR (subcutaneous administration of 1.2 mg/d, 1.8 mg/d, 2.4 mg/d or 3 mg/d) had an average weight loss of 4.8-7.2 kg, the two-year extended experiment of which also showed similar results (88, 89)
According to a KFF poll, 62% of adults taking GLP-1 drugs reported using them to manage a chronic condition such as diabetes or heart disease, while about four in 10 said they were prescribed GLP-1s primarily to lose weight
These parameters included the levels of total protein (Catalog No.: MBS165636), albumin (Catalog No.: MBS2881881), aspartate transaminase (AST) (Catalog No.: MBS740867), alanine transaminase (ALT) (Catalog No.: MBS266858), lactate dehydrogenase (LDH) (Catalog No.: MBS263022), triglycerides (Catalog No.: MBS1601908), total cholesterol (Catalog No.: MBS1601900), high-density lipoprotein (HDL) (Catalog No.: MBS040311), and low-density lipoprotein (LDL) (Catalog No.: MBS269281)
Their common side effects include nausea, diarrhea, and constipation, although they tend to be mild to moderate when you use them properly and improve as your body gets used to the medication
Given the substantial disease burden and adverse health outcomes associated with this comorbidity, interventions aimed at reducing this risk for depression in the Type 2 diabetes population are crucial, particularly among older adults who are disproportionately affected by both conditions. Guo noted that previous research suggested that GLP-1RAs a drug also used to treat obesity and kidney disease may alleviate depression symptoms due to its ability to cross the blood-brain barrier
Nutrition and metabolic insights , 9 , 2530
![GLP-1 Agonists Can Be Heaven or Hell Dependent Upon Dopaminergic Genetic/Epigenetic Antecedents[v1]](https://www.preprints.org/frontend/picture/ms_xml/manuscript/c9c3cd16d3db64faa79714c50b5bb790/preprints-181961-g001.png)
